With more than 17 million euros raised in total Invectys also benefits from 850,000€ in financing from Bpifrance. Invectys announces fundraising of an additional…
Invectys starts the third dose level of its phase I clinical trial evaluating INVAC-1, an innovative anti-cancer therapeutic vaccine A new clinical hope in cancer…
Invectys raises 1.7 million Euros more to finance the clinical development of its therapeutic cancer vaccine With a total of 10 million euros raised, new premises,…
Invectys Initiates Phase I Clinical Trial Evaluating INVAC-1 Therapeutic Vaccine for Cancer Patients A new clinical hope in cancer immunotherapy Paris, May 12th,…
Invectys receives ANSM approval to start clinical trial for INVAC-1, its leading anticancer immunotherapy INVAC-1 is an anticancer candidate vaccine targeting…
A new clinical hope in cancer immunotherapy Paris, May 12th, 2015 – Invectys announces today that it has initiated a phase I clinical trial of its immunotherapeutic…
First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G François Anna, Elodie Bole-Richard, Joel LeMaoult, Marie Escande, Martin Lecomte,…
